Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2- chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 2, 2005, Pages 891-905

  Bodenstein, Johannes ^b   Venter, Daniel P ^a   Brink, Christiaan B ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 4 DIPHENYLACETOXYPIPERIDINE; ALPHA 2A ADRENERGIC RECEPTOR; BENEXTRAMINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MUSCARINIC RECEPTOR; PHENOXYBENZAMINE; SEROTONIN 2A RECEPTOR; SULFUR 35;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL LINE; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; RADIOASSAY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CYCLIC AMP; CYSTAMINE; DIPHENYLACETIC ACIDS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; INOSITOL PHOSPHATES; LIGANDS; PHENOXYBENZAMINE; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MUSCARINIC; SECOND MESSENGER SYSTEMS; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION;

EID: 22944471442     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083568     Document Type: Article

References (69)

1. Adham N, Ellerbrock B, Hartig P, Weinshank RL, and Branchek T (1993) Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol 43:427-433.
2. 2- autoreceptors: agonist dissociation constants and recovery after irreversible activation. Br J Pharmacol 108:370-375.
3. Amobi NI and Smith IC (1995) Differential inhibition in the human vas deferens by phenoxybenzamine: a possible mechanism for its contraceptive action. J Reprod Fertil 103:215-221.
4. 1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology 38:525-532.
5. 2-receptor-mediated effects. Br J Pharmacol 75:573-578.
6. Belleau B, Benfey BG, Melchiorre C, and Montambault M (1982b) Inhibition of adrenaline-induced platelet aggregation by the -adrenoceptor blocking drug benextramine. Br J Pharmacol 76:253-257.
7. Benfey BG, Belleau B, Brasili L, Giannella M, and Melchiorre C (1980) Irreversible alpha adrenoceptor blocking effects and reversible muscarinic blocking and nicotinic blocking effects of tetramine disulfides on the heart. Can J Physiol Pharmacol 58:1477-1483.
8. Berridge MJ (1993) Inositol trisphosphate and calcium signalling. Nature (Lond) 361:315-325.
9. Bleasdale JE and Fisher SK (1993) Use of U-73122 as an inhibitor of phospholipase C-dependent processes. Neuroprotocols 3:125-133.
10. Boess FG and Martin IL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33:275-317.
11. 2C receptor antagonist. Neuropharmacology 36:621-629.
12. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
13. 2- adrenoceptors by pyrextramine and benextramine in isolated guinea pig ileum. Life Sci 38:1633-1640.
14. Brasili L, Melchiorre C, Belleau B, and Benfey BG (1980) Reactivation by cysteamine of vascular alpha adrenoceptors blocked by the tetramine disulfide benextramine and interaction of benextramine with phenoxybenzamine. Can J Physiol Pharmacol 58:1490-1493.
15. s. J Pharmacol Exp Ther 294:539-547.
16. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, Leurs R, and Smit M (2001) Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 276:1133-1137.
17. 2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system. J Biol Chem 269:5730-5734.
18. Crago RM, Eckholdt JW, and Wismell JG (1967) Pheochromocytoma. Treatment with alpha- and beta-adrenergic blocking drugs. J Am Med Assoc 202:870-874.
19. Eason MG, Kurose H, Holt BD, Raymond JR, and Liggett SB (1992) Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4 and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem 267:15795-15801.
20. Eglen RM, Reddy H, and Watson N (1994) Selective inactivation of muscarinic receptor subtypes. Int J Biochem 26:1357-1368.
21. Ehlert FJ and Griffin MT (1998) The use of irreversible ligands to inactivate receptor subtypes: 4-DAMP mustard and muscarinic receptors in smooth muscle. Life Sci 62:1659-1664.
22. Frang H, Cockroft V, Karskela T, Scheinin M, and Marjamäki A (2001) Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem 276:31279-31284.
23. Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, in Advances in Drug Research (Harper NJ and Simmonds AB eds), vol 3, pp 21-55, Academic Press, New York.
24. Giardinà D, Crucianelli M, Angeli P, Buccioni M, Gulini U, Marucci G, Sagratini G, and Melchiorre C (2002) Structure-activity relationships among novel phenoxybenzamine-related β-chloroethylamines. Bioorg Med Chem 10:1291-1303.
25. 1-antagonist activity of new prazosin- and benextraminerelated tetramine disulfides. Eur J Med Chem 32:9-20.
26. Giardinà D, Crucianelli M, Marucci G, Paparelli F, and Melchiorre C (1995) Synthesis and α-adrenoceptor blocking properties of phenoxybenzamine-related (2-chloroethyl)-(2,3-dihidrobenzo[1,4]dioxin-2- ylmethyl)-(2-phenoxyethyl) amines. Bioorg Med Chem 3:85-94.
27. Godfrey P (1992) Signal Transduction: A Practical Approach (Milligan G ed) pp 105-121, IRL Press, Oxford.
28. Graber SG, Figler RA, and Garrison JC (1992) Expression and purification of functional G protein α subunits using a baculovirus expression system. J Biol Chem 267:1271-1278.
29. Herepath ML and Broadley KJ (1990) Affinities of full agonists for cardiac β-adrenoceptors calculated by use of in vitro desensitisation. Naunyn-Schmiedeberg's Arch Pharmacol 341:525-533.
30. Hieble JP, Caine M, and Zalaznik E (1985) In vitro characterization of the α-adrenoceptors in human prostate. Eur J Pharmacol 107:111-117.
31. Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K, Sato A, Hasegawa T, Nishikibe M, Mitsuya M, et al. (2001) Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel muscarinic antagonist with M2-sparing antagonistic activity. J Pharmacol Exp Ther 297:790-797.
32. Jenkinson DH (2003) Classical approaches to the study of drug-receptor interactions, in Textbook of Receptor Pharmacology (Foreman JC and Johansen T eds) pp 3-78, CRC Press, Boca Raton.
33. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction, Lippincott-Raven Publishers, Philadelphia.
34. 1A receptors: effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats. Psychopharmacology (Berl) 149:377-387.
35. Kukkonen J, Ojala P, Näsman J, Hämäläinen H, Heikkilä J, and Åkerman KE (1992) Muscarinic receptor subtypes in human neuroblastoma cell lines SH-SY5Y and IMR-32 as determined by receptor binding, Ca++ mobilization and northern blotting. J Pharmacol Exp Ther 263:1487-1493.
36. Lambert DG, Ghataorre AS, and Nahorski SR (1989) Muscarinic receptor binding characteristics of a human neuroblastoma SK-N-SH and its clones SH-SY5Y and SH-EP1. Eur J Pharmacol 165:71-77.
37. Lew MJ and Angus JA (1984) Reversible inhibition of neuronal uptake by benextramine, an irreversible presynaptic α-adrenoceptor antagonist. Eur J Pharmacol 98:27-34.
38. 2-adrenergic receptors in human erythroleukemia (HEL) cells. Studies with the irreversible antagonist benextramine. Mol Pharmacol 33:51-57.
39. Melchiorre C (1981) Tetramine disulfides: a new tool in α-adrenergic pharmacology. Trends Pharmacol Sci 2:209-211.
40. Melchiorre C, Benfey BG, Brasili L, Bolger B, and Belleau B (1979) Recent Advances in Receptor Chemistry (Gualtieri F, Giannella M, and Melchiorre C eds) pp 207-220, Elsevier/North-Holland Biomedical Press, Amsterdam.
41. Melchiorre C and Gallucci P (1983) The irreversible α-blocker benextramine interacts with two different thiol groups. Farm Ed Sci 38:950-956.
42. Melchiorre C, Romualdi P, Bolognesi ML, Donatini A, and Ferri S (1994) Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. Eur J Pharmacol 265:93-98.
43. 1-adenosine receptor reserve in guinea-pig atrium. Br J Pharmacol 123:1425-1433.
44. Neubig RR, Spedding M, Kenakin T, and Christopoulos A (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
45. Olianas MC and Onali P (1991) Muscarinic stimulation of adenylate cyclase activity of rat olfactory bulb. I. Analysis of agonist sensitivity. J Pharmacol Exp Ther 259:673-679.
46. Piascik MT, Kusiak JW, Pitha J, Butler BT, Le HT, and Babich M (1988) Alkylation of alpha-1 receptors with a chemically reactive analog of prazosin reveals low affinity sites for norepinephrine in rabbit aorta. J Pharmacol Exp Ther 246:1001-1011.
47. Ragheb F, Molina-Holgado E, Cui Q-L, Khorchid A, Liu H-N, Larocca JN, and Almazan G (2001) Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J Neurochem 77:1396-1406.
48. 3H]ketanserin recognition sites in rat striatum. J Neurochem 49:1833-1838.
49. Ruffolo RR and Hieble JP (1999) Adrenoceptor pharmacology: urogenital applications. Eur Urol 36 (Suppl 1):17-22.
50. Salomon Y, Londos C, and Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
51. 3 receptor interactions. J Pharmacol Exp Ther 289:464-476.
52. Slowiejko DM, McEwen EL, Ernst SA, and Fisher SK (1996) Muscarinic receptor sequestration in SH-SY5Y neuroblastoma cells is inhibited when clathrin distribution is perturbed. J Neurochem 66:186-196.
53. q/11. Eur J Pharmacol 372:325-328.
54. 35S]GTPγS binding. Eur J Pharmacol 320:267-275.
55. Sternweis PC and Robishaw JD (1984) Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 259:13806-13813.
56. 2-adrenergic receptors by benextramine. Mol Pharmacol 31:89-96.
57. Thomas EA, Hsu HH, Griffin MT, Hunter AL, Luong T, and Ehlert FJ (1992) Conversion of N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) to an aziridinium ion and its interaction with muscarinic receptors in various tissues. Mol Pharmacol 41:718-726.
58. 2D-adrenergic receptor regulated G protein activation in PC12 cell membranes. Pharmacology 52:252-262.
59. 2-adrenoceptor mediated vasoconstriction in pithed rats. Naunyn-Schmiedeberg's Arch Pharmacol 329:404-413.
60. 35S]GTPγS and cAMP functional assays. Eur J Pharmacol 411:211-221.
61. Van der Graaf PH and Danhof M (1997) On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentrationeffect curves following irreversible receptor inactivation. J Pharmacol Toxicol Methods 38:81-85.
62. Van der Graaf PH and Stam WB (1999) Analysis of receptor inactivation experiments with the operational model of agonism yields correlated estimates of agonist affinity and efficacy. J Pharmacol Toxicol Methods 41:117-125.
63. Van der Graaf PH, Stam WB, and Saxena PR (1996) Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery. Eur J Pharmacol 300:211-214.
64. Van Ginneken CAM (1977) Kinetics of drug-receptor interaction, in Kinetics of Drug Action (Van Rossum JM ed) pp 357-411, Springer-Verlag, Berlin.
65. s activation. Mol Pharmacol 56:1005-1013.
66. i assays in transfected cells. Methods Enzymol 238:81-94.
67. Yang Q and Lanier SM (1999) Influence of G protein type on agonist efficacy. Mol Pharmacol 56:651-656.
68. Zhu BT (1993) The competitive and noncompetitive antagonism of receptor-mediated drug actions in the presence of spare receptors. J Pharmacol Toxicol Methods 29:85-91.
69. Zwart R and Vijverberg HP (1997) Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol 52:886-895.